背景:据广泛报道,各种抗风湿中药(TCM)通过调节类风湿关节炎(RA)和骨关节炎(OA)的异常产生,装配,和NOD样受体热蛋白结构域相关蛋白3(NLRP3)炎性体的激活。这些中药包括从中草药中分离的单体,中草药提取物,和具有悠久应用历史的中药配方。
目的:本文旨在总结和分析有关NLRP3炎性体及其在RA和OA发病机制中的作用。我们还回顾了关于TCM通过调节NLRP3炎性体在RA和OA中的治疗机制的现有知识。
方法:我们搜索了关键字为“NLRP3炎症体”的相关文章,“中药,\"\"中草药,\"\"类风湿性关节炎,“和”骨关节炎。\“从建设之日起至2023年4月19日,在医学中英文数据库中进行了信息检索,包括PubMed,MEDLINE,WebofScience,Scopus,奥维德,中国国家知识基础设施(CNKI),中国生物医学文献数据库(CBM),中国科技期刊数据库(VIP),和中国在线期刊(COJ)。
结果:根据检索结果,35TCM已被证明通过靶向NLRP3炎性体来缓解RA,包括六种传统的中国处方,七种中草药提取物,以及从传统中药和配方中提取的22种单体。此外,23TCM已显示出抗OA作用,具有调节NLRP3炎性体的能力,包括五个传统的中国处方,一种中草药提取物,和17种来自中草药的单体。
结论:我们总结了NLRP3炎性体在RA和OA发病中的关键作用的机制研究。此外,还对RA和OA治疗中具有NLRP3炎性体靶标的TCM进行了综述.我们的工作有助于更好地应用中药在RA和OA的补充和替代疗法中。
BACKGROUND: It has been widely reported that various anti-rheumatic traditional Chinese medicines (TCMs) ameliorate rheumatoid arthritis (RA) and osteoarthritis (OA) through regulating the abnormal production, assembly, and activation of the NOD-like receptor thermal protein domain-associated protein 3 (NLRP3) inflammasome. These TCMs include monomers isolated from Chinese herbs, extracts of Chinese herbs, and Chinese medical formulae with a lengthy application history.
OBJECTIVE: This review aimed to summarize and analyze the published articles about the NLRP3 inflammasome and its role in the pathogenesis of RA and OA. We also reviewed existing knowledge on the therapeutic mechanism of TCMs in RA and OA via the regulation of the NLRP3 inflammasome.
METHODS: We searched for relevant articles with the keywords \"NLRP3 inflammasome\", \"traditional Chinese medicine,\" \"Chinese herbal drugs,\" \"rheumatoid arthritis,\" and \"osteoarthritis.\" The information retrieval was conducted in medical Chinese and English databases from the date of construction to April 19, 2023, including PubMed, MEDLINE, Web of Science, Scopus, Ovid, China National Knowledge Infrastructure (CNKI), Chinese Biomedicine Literature Database (CBM), Chinese Science and Technology Periodicals Database (VIP), and China Online Journals (COJ).
RESULTS: According to retrieval results, 35 TCMs have been demonstrated to relieve RA by targeting the NLRP3 inflammasome, including six traditional Chinese prescriptions, seven extracts of Chinese herbs, and 22 monomers extracted from traditional Chinese herbs and formulae. Additionally, 23 TCMs have shown anti-OA effects with abilities to modulate the NLRP3 inflammasome, including five traditional Chinese prescriptions, one extract of Chinese herbs, and 17 monomers from Chinese herbs.
CONCLUSIONS: We summarized mechanism research about the pivotal roles of the NLRP3 inflammasome in the pathogenesis of RA and OA. Moreover, a review of TCMs with targets of the NLRP3 inflammasome in RA and OA treatment was also conducted. Our work is conducive to a better application of TCMs in complementary and alternative therapies in RA and OA.